SELLAS Life Sciences anticipates a pivotal 2025 with key clinical milestones for its hematologic malignancy therapies, including data readouts and regulatory feedback.
The Independent Data Monitoring Committee (IDMC) recommended continuing SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).
The FDA granted priority review to fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low/ultra-low breast cancer, potentially expanding treatment options for this patient subgroup.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.